Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03145181 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Hematological Malignancies, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 302
- Enrollment target
- 13
- Study locations
NCT03145181: Active Phase 1 study of Hematological Malignancies, sponsored by Janssen Research & Development.
NCT03145181 is a Phase 1 study of Hematological Malignancies that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 302 participants, below the 758-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (60% lower). The trial reports 13 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03145181, a Phase 1 study of Hematological Malignancies, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 302 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.
Primary Outcome
The Dose Limiting Toxicities (DLTs) are based on drug related adverse events and defined as any of the following events: hematological / non hematological toxicity of Grade 3 or higher.
Conditions Studied
Interventions
- DRUG Teclistamab (IV)
- DRUG Teclistamab(SC)
Study Locations (13)
Other
- Hospices Civils de Lyon HCL - Lyon
- CHRU Tours Hopital Bretonneau - Tours
- VU Medisch Centrum - Amsterdam
- Hosp. Univ. Germans Trias I Pujol - Badalona
- Hosp Clinic de Barcelona - Barcelona
- Clinica Univ. de Navarra - Pamplona
- Hosp Clinico Univ de Salamanca - Salamanca
- Haematology Centre, R 51 - Stockholm
California
- City of Hope - Duarte
Colorado
- Colorado Blood Cancer Institute - Denver
New York
- Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects - New York
North Carolina
- Levine Cancer Institute - Charlotte
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2017-05-16 |
| Est. Completion | 2027-05-28 |
| Phase | Phase 1 |
What the registry record for NCT03145181 still lists
NCT03145181 is an interventional study that assigns participants to a tested intervention. The registered 302 participants enrollment target is mid-sized for trials with a published cap, below the 758-participant average among 16 other Hematological Malignancies trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Hematological Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Teclistamab (IV) is the first listed.
NCT03145181 lists 13 locations in 6 states (Other, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT03145181 about?
NCT03145181 is a clinical study titled "Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.
What is the current status of trial NCT03145181?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 302 participants. The study started on 2017-05-16. Estimated completion is 2027-05-28.
What conditions does trial NCT03145181 study?
This clinical trial studies the following conditions: Hematological Malignancies.
What interventions are being tested in trial NCT03145181?
The interventions under investigation include: Teclistamab (IV) (DRUG), Teclistamab(SC) (DRUG).
Who is sponsoring clinical trial NCT03145181?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03145181 being conducted?
This trial has 13 study locations across California, Colorado, New York, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03145181's enrollment target sits among peer trials
302 4th of 16 higher than 13 of 16 other Hematological Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematological Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
RECRUITING · Phase 1
-
Durvalumab and Tremelimumab for Pediatric Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Study of AZD9829 in CD123+ Hematological Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI